Location: | Oxford |
---|---|
Salary: | £34,982 to £40,855 per annum |
Hours: | Full Time |
Contract Type: | Fixed-Term/Contract |
Placed On: | 10th April 2025 |
---|---|
Closes: | 8th May 2025 |
Job Ref: | 179167 |
Are you passionate about the future of genetic medicines? Do you want to contribute to pioneering research with real translational potential? Join the Gene Medicine Group at the University of Oxford and help shape the future of gene therapy. We’re developing a next-generation delivery platform using Lentivirus-derived nanoparticles engineered to package CRISPR RNPs instead of viral genomes. This platform offers high potency, with improved safety, avoiding insertional mutagenesis and minimizing genotoxicity.
This is an exciting opportunity to be part of a cutting-edge project developing next-generation genome editing therapies. In this role you will support the incorporation of third-generation genome editors into LVNPs, to correct ‘gain-of-function’ mutations through gene correction or replacement strategies. You will help refine a scalable, cGMP-compliant manufacturing pipeline and contribute to disease modelling using iPSCs and in vivo delivery studies.
This is a unique opportunity to be part of a translational research programme advancing gene editing tools towards clinical application.
Start date: Summer 2025
Closing date: 12 noon, 8 May 2025
Interviews: Week commencing 26 May 2025
Please quote reference 179167 in all correspondence. For an informal discussion, please contact Dr Jakob Haldrup (jakob.haldrupjensen@ndcls.ox.ac.uk).
Type / Role:
Subject Area(s):
Location(s):